Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Florence Ader; Maude Bouscambert-Duchamp; Maya Hites; Nathan Peiffer-Smadja; Julien Poissy; Drifa Belhadi; Alpha Diallo; Minh-Patrick Lê; Gilles Peytavin; Thérèse Staub; Richard Greil; Jérémie Guedj; Jose-Artur Paiva; Dominique Costagliola; Yazdan Yazdanpanah; Charles Burdet; France Mentré

doi:10.1016/S1473-3099(21)00485-0

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Lê, Gilles Peytavin, Thérèse Staub, Richard Greil (Co-author), Jérémie Guedj, Jose-Artur Paiva, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentré

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

241 Citations (Web of Science)

Original language	English
Pages (from-to)	209-221
Journal	LANCET INFECTIOUS DISEASES
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/S1473-3099(21)00485-0
Publication status	Published - 2022

Keywords

EFFICACY

Access to Document

10.1016/S1473-3099(21)00485-0

Cite this

Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Lê, M.-P., Peytavin, G., Staub, T., Greil, R., Guedj, J., Paiva, J.-A., Costagliola, D., Yazdanpanah, Y., Burdet, C., & Mentré, F. (2022). Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. LANCET INFECTIOUS DISEASES, 22(2), 209-221. https://doi.org/10.1016/S1473-3099(21)00485-0

@article{95b19fc8d1c24303a9e78603f6f5f2c1,

title = "Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.",

keywords = "EFFICACY",

author = "Florence Ader and Maude Bouscambert-Duchamp and Maya Hites and Nathan Peiffer-Smadja and Julien Poissy and Drifa Belhadi and Alpha Diallo and Minh-Patrick L{\^e} and Gilles Peytavin and Th{\'e}r{\`e}se Staub and Richard Greil and J{\'e}r{\'e}mie Guedj and Jose-Artur Paiva and Dominique Costagliola and Yazdan Yazdanpanah and Charles Burdet and France Mentr{\'e}",

note = "Greil: epartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; AGMT, Salzburg, Austria. Egle: nein",

year = "2022",

doi = "10.1016/S1473-3099(21)00485-0",

language = "English",

volume = "22",

pages = "209--221",

journal = "LANCET INFECTIOUS DISEASES",

issn = "1473-3099",

number = "2",

}

Ader, F, Bouscambert-Duchamp, M, Hites, M, Peiffer-Smadja, N, Poissy, J, Belhadi, D, Diallo, A, Lê, M-P, Peytavin, G, Staub, T, Greil, R, Guedj, J, Paiva, J-A, Costagliola, D, Yazdanpanah, Y, Burdet, C & Mentré, F 2022, 'Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.', LANCET INFECTIOUS DISEASES, vol. 22, no. 2, pp. 209-221. https://doi.org/10.1016/S1473-3099(21)00485-0

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. / Ader, Florence; Bouscambert-Duchamp, Maude; Hites, Maya et al.
In: LANCET INFECTIOUS DISEASES, Vol. 22, No. 2, 2022, p. 209-221.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

AU - Ader, Florence

AU - Bouscambert-Duchamp, Maude

AU - Hites, Maya

AU - Peiffer-Smadja, Nathan

AU - Poissy, Julien

AU - Belhadi, Drifa

AU - Diallo, Alpha

AU - Lê, Minh-Patrick

AU - Peytavin, Gilles

AU - Staub, Thérèse

AU - Greil, Richard

AU - Guedj, Jérémie

AU - Paiva, Jose-Artur

AU - Costagliola, Dominique

AU - Yazdanpanah, Yazdan

AU - Burdet, Charles

AU - Mentré, France

N1 - Greil: epartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; AGMT, Salzburg, Austria. Egle: nein

PY - 2022

Y1 - 2022

KW - EFFICACY

U2 - 10.1016/S1473-3099(21)00485-0

DO - 10.1016/S1473-3099(21)00485-0

M3 - Original Article

C2 - 34534511

SN - 1473-3099

VL - 22

SP - 209

EP - 221

JO - LANCET INFECTIOUS DISEASES

JF - LANCET INFECTIOUS DISEASES

IS - 2

ER -